CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rodin Therapeutics, a biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, today announced the appointment of Samantha Singer, Chief Operating Officer of the Broad Institute of MIT and Harvard, as an independent member of the company’s Board of Directors. Mrs. Singer is a highly-regarded biopharmaceutical industry executive with over 15 years of international business and corporate strategy experience.
